Skip to main content
SpringerLink
Log in

Genetic Cholestatic Disorders

  • Chapter
  • First Online:
Pediatric Hepatology and Liver Transplantation

  • 1814 Accesses

Abstract

The knowledge of the underlying aetiology of neonatal idiopathic hepatitis and the so-called “intrahepatic” cholestasis has been rapidly expanding in the last decade, and great advances in genetic testing have clarified that the vast majority of these conditions are monogenic liver disorders. Among those referred to as progressive familial intrahepatic cholestases (PFICs), the level of serum GGT is a good discriminant to guide the initial evaluation, being low/normal in Byler disease, BSEP deficiency, TJP2 deficiency, FXR deficiency and MYO5B deficiency, and increased only in MDR3 deficiency; however genetic testing is needed to reach a definite categorisation. In bile acid synthesis defects, normal serum bile acid is a clue to the diagnosis, although mass spectrometry is required to characterise the type of defect. Other well-known conditions such as Alagille syndrome and alpha-1 antitrypsin deficiency are more common and less challenging to recognise. In this chapter we discuss the clinical features of canalicular transport and tight junction defects, bile acid synthesis defects, biliary developmental defects and metabolic disorders that can present with neonatal/infantile cholestasis, providing also a rational approach to the diagnosis of the rarest forms as well as information on their current standard of care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4(1):1. BioMed Central.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S26–35.

    Article  CAS  PubMed  Google Scholar 

  3. Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. Acta Paediatr. 2007;90(1):88–92. Wiley/Blackwell (10.1111).

    Article  Google Scholar 

  4. Kamath BM, Chen Z, Romero R, Fredericks EM, Alonso EM, Arnon R, et al. Quality of life and its determinants in a multicenter cohort of children with Alagille syndrome. J Pediatr. 2015;167(2):390–3.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46(4):326–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim M-S, Kim KH, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713. Nature Publishing Group.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Qiu Y-L, Gong J-Y, Feng J-Y, Wang R-X, Han J, Liu T, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis. Hepatology. 2017;65(5):1655–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5):1645–55.

    Article  CAS  PubMed  Google Scholar 

  9. Mehaidib Al A, Shahrani Al A. 1381 progressive familial intrahepatic cholestasis in ARABS. J Hepatol. 2013;58:S555–6.

    Article  Google Scholar 

  10. Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation. 2007;84(10):1361–3.

    Article  PubMed  Google Scholar 

  11. Wanty C, Joomye R, Van Hoorebeek N, Paul K, Otte JB, Reding R, et al. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol Belg. 2004;67(4):313–9.

    CAS  PubMed  Google Scholar 

  12. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis. 2001;21(4):551–62. Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662.

    Article  CAS  PubMed  Google Scholar 

  13. Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol. 2003;39(3):447–52.

    Article  PubMed  Google Scholar 

  14. Demeilliers C, Jacquemin E, Barbu V, Mergey M, Paye F, Fouassier L, et al. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology. 2006;43(5):1125–34. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  15. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology. 2006;44(4):778–87. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  16. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4Gene mutations: pathophysiology and clinical aspects. Semin Liver Dis. 2010;30(2):134–46. © Thieme Medical Publishers.

    Article  CAS  PubMed  Google Scholar 

  17. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology. 2006;44(1):195–204. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  18. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology. 2004;126(3):756–64.

    Article  CAS  PubMed  Google Scholar 

  19. Alvarez L, Jara P, Sánchez-Sabaté E, Hierro L, Larrauri J, Diaz MC, et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet. 2004;13(20):2451–60.

    Article  CAS  PubMed  Google Scholar 

  20. van der Mark VA, de Jonge HR, Chang J-C, Ho-Mok KS, Duijst S, Vidović D, et al. The phospholipid flippase ATP8B1 mediates apical localization of the cystic fibrosis transmembrane regulator. Biochim Biophys Acta. 2016;1863(9):2280–8.

    Article  PubMed  CAS  Google Scholar 

  21. Egawa H, Yorifuji T, Sumazaki R, Kimura A, Hasegawa M, Tanaka K. Intractable diarrhea after liver transplantation for Byler’s disease: successful treatment with bile adsorptive resin. Liver Transpl. 2002;8(8):714–6.

    Article  PubMed  Google Scholar 

  22. Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerová D, Rayner A, Dutton L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134(4):1203–14.

    Article  CAS  PubMed  Google Scholar 

  23. Thompson R, Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin Liver Dis. 2001;21(4):545–50. Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662.

    Article  CAS  PubMed  Google Scholar 

  24. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, et al. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G58–67. American Physiological Society.

    Article  CAS  PubMed  Google Scholar 

  25. Lam P, Pearson CL, Soroka CJ, Xu S, Mennone A, Boyer JL. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol. 2007;293(5):C1709–16. American Physiological Society.

    Article  CAS  PubMed  Google Scholar 

  26. Amigo L, Mendoza H, Zanlungo S, Miquel JF, Rigotti A, González S, et al. Enrichment of canalicular membrane with cholesterol and sphingomyelin prevents bile salt-induced hepatic damage. J Lipid Res. 1999;40(3):533–42.

    CAS  PubMed  Google Scholar 

  27. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1–2):17–29.

    Article  CAS  PubMed  Google Scholar 

  28. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap—bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488–98. Nature Publishing Group.

    Article  CAS  PubMed  Google Scholar 

  29. Lapierre LA, Kumar R, Hales CM, Navarre J, Bhartur SG, Burnette JO, et al. Myosin Vb is associated with plasma membrane recycling systems. Guidotti G, editor. Mol Biol Cell. 2001;12(6):1843–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Roland JT, Kenworthy AK, Peranen J, Caplan S, Goldenring JR. Myosin Vb interacts with Rab8a on a tubular network containing EHD1 and EHD3. Brennwald P, editor. Molecular Biology of the Cell. 2007;18(8):2828–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Swiatecka-Urban A, Talebian L, Kanno E, Moreau-Marquis S, Coutermarsh B, Hansen K, et al. Myosin Vb is required for trafficking of the cystic fibrosis transmembrane conductance regulator in Rab11a-specific apical recycling endosomes in polarized human airway epithelial cells. J Biol Chem. 2007;282(32):23725–36. American Society for Biochemistry and Molecular Biology.

    Article  CAS  PubMed  Google Scholar 

  32. Wakabayashi Y, Dutt P, Lippincott-Schwartz J, Arias IM. Rab11a and myosin Vb are required for bile canalicular formation in WIF-B9 cells. Proc Natl Acad Sci U S A. 2005;102(42):15087–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Girard M, Lacaille F, Verkarre V, Mategot R, Feldmann G, Grodet A, et al. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease. Hepatology. 2014;60(1):301–10. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  34. Gonzales E, Taylor SA, Davit-Spraul A, Thébaut A, Thomassin N, Guettier C, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65(1):164–73.

    Article  CAS  PubMed  Google Scholar 

  35. Sawada N. Tight junction-related human diseases. Pathol Int. 2013;63(1):1–12. Wiley/Blackwell (10.1111).

    Article  CAS  PubMed  Google Scholar 

  36. Grosse B, Cassio D, Yousef N, Bernardo C, Jacquemin E, Gonzales E. Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability. Hepatology. 2012;55(4):1249–59. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  37. Carlton VEH, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet. 2003;34(1):91–6. Nature Publishing Group.

    Article  CAS  PubMed  Google Scholar 

  38. Kim M-A, Kim Y-R, Sagong B, Cho H-J, Bae JW, Kim J, et al. Genetic analysis of genes related to tight junction function in the Korean population with non-syndromic hearing loss. Weber CR, editor. PLoS One. 2014;9(4):e95646. Public Library of Science.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Paganelli M, Stéphenne X, Gilis A, Jacquemin E, Henrion-Caude A, Girard M, et al. Neonatal ichthyosis and sclerosing cholangitis syndrome: extremely variable liver disease severity from claudin-1 deficiency. J Pediatr Gastroenterol Nutr. 2011;53(3):350–4.

    Article  PubMed  Google Scholar 

  40. Setchell KDR, Heubi JE. Defects in bile acid biosynthesis-diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006;43(Suppl 1):S17–22.

    Article  CAS  PubMed  Google Scholar 

  41. Heubi J, Setchell K, Bove K. Inborn errors of bile acid metabolism. Semin Liver Dis. 2007;27(3):282–94.

    Article  CAS  PubMed  Google Scholar 

  42. Jacquemin E, Setchell KDR, O’Connell NC, Bernard O. A new cause of progressive intrahepatic cholestasis: 3β-Hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr. 1994;125(3):379–84.

    Article  CAS  PubMed  Google Scholar 

  43. Shneider BL, Setchell KDR, Whitington PF, Neilson KA, Suchy FJ. Δ4-3-Oxosteroid 5β-reductase deficiency causing neonatal liver failure and hemochromatosis. J Pediatr. 1994;124(2):234–8.

    Article  CAS  PubMed  Google Scholar 

  44. Daugherty CC, Setchell KD, Heubi JE, Balistreri WF. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency). Hepatology. 1993;18(5):1096–101.

    Article  CAS  PubMed  Google Scholar 

  45. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis. 2008;31(S2):241–5.

    Article  Google Scholar 

  46. Vaz FM, Bootsma AH, Kulik W, Verrips A, Wevers RA, Schielen PC, et al. A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios. J Lipid Res. 2017;58(5):1002–7. American Society for Biochemistry and Molecular Biology.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2002;25(6):501–13.

    Article  CAS  PubMed  Google Scholar 

  48. Gong J-Y, Setchell KDR, Zhao J, Zhang W, Wolfe B, Lu Y, et al. Severe neonatal cholestasis in cerebrotendinous xanthomatosis: genetics, immunostaining, mass spectrometry. J Pediatr Gastroenterol Nutr. 2017;65(5):561–8.

    Article  PubMed  Google Scholar 

  49. Heubi J, Setchell K, Bove K. Inborn errors of bile acid metabolism. Semin Liver Dis. 2007;27(3):282–94. Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

    Article  CAS  PubMed  Google Scholar 

  50. Heubi JE, Setchell KDR, Jha P, Buckley D, Zhang W, Rosenthal P, et al. Treatment of bile acid amidation defects with glycocholic acid. Hepatology. 2015;61(1):268–74. 1st ed. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  51. Setchell KD, Schwarz M, O’Connell NC, Lund EG, Davis DL, Lathe R, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest. 1998;102(9):1690–703. American Society for Clinical Investigation.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ueki I, Kimura A, Nishiyori A, Chen H-L, Takei H, Nittono H, et al. Neonatal cholestatic liver disease in an Asian patient with a homozygous mutation in the oxysterol 7α-hydroxylase gene. J Pediatr Gastroenterol Nutr. 2008;46(4):465–9.

    Article  PubMed  Google Scholar 

  53. Goldfischer S, Moore CL, Johnson AB, Spiro AJ, Valsamis MP, Wisniewski HK, et al. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science. 1973;182(4107):62–4.

    Article  CAS  PubMed  Google Scholar 

  54. Poll-The BT, Saudubray JM, Ogier H, Schutgens RB, Wanders RJ, Schrakamp G, et al. Infantile Refsum’s disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 1986;9(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  55. Goldfischer S, Collins J, Rapin I, Coltoff-Schiller B, Chang CH, Nigro M, et al. Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies. Science. 1985;227(4682):67–70.

    Article  CAS  PubMed  Google Scholar 

  56. Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. J Pediatr. 1964;64(2):210–7.

    Article  CAS  PubMed  Google Scholar 

  57. Zhou Y, Zhang J. Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome: from molecular genetics to clinical features. Ital J Pediatr. 2014;40(1):1. BioMed Central.

    Article  CAS  Google Scholar 

  58. Gissen P, Tee L, Johnson CA, Genin E, Caliebe A, Chitayat D, et al. Clinical and molecular genetic features of ARC syndrome. Hum Genet. 2006;120(3):396–409.

    Article  CAS  PubMed  Google Scholar 

  59. Peterson MR, Emr SD. The class C Vps complex functions at multiple stages of the vacuolar transport pathway. Traffic. 2001;2(7):476–86. Wiley/Blackwell (10.1111).

    Article  CAS  PubMed  Google Scholar 

  60. Cullinane AR, Straatman-Iwanowska A, Zaucker A, Wakabayashi Y, Bruce CK, Luo G, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet. 2010;42(4):303–12. Nature Publishing Group.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. Appl Clin Genet. 2016;9:75–82. Dove Press.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Danks DM, Campbell PE, Jack I, Rogers J, Smith AL. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child. 1977;52(5):360–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999;29(3):822–9. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  64. Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 2004;109(11):1354–8. American Heart Association, Inc.

    Article  PubMed  Google Scholar 

  65. Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol. 2013;9(7):409–18.

    Article  CAS  PubMed  Google Scholar 

  66. Mašek J, Andersson ER. The developmental biology of genetic Notch disorders. Development. 2017;144(10):1743–63. Oxford University Press for the Company of Biologists Limited.

    Article  PubMed  CAS  Google Scholar 

  67. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology. 2009;136(7):2325–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology. 2008;48(2):607–16. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  69. Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T. The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology. 2004;127(6):1775–86.

    Article  CAS  PubMed  Google Scholar 

  70. Walter TJ, Vanderpool C, Cast AE, Huppert SS. Intrahepatic bile duct regeneration in mice does not require Hnf6 or notch signaling through Rbpj. Am J Pathol. 2014;184(5):1479–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Riely CA. Arteriohepatic dysplasia: a benign syndrome of intrahepatic cholestasis with multiple organ involvement. Ann Intern Med. 1979;91(4):520–7. American College of Physicians.

    Article  CAS  PubMed  Google Scholar 

  72. Pavanello M, Severino M, D’Antiga L, Castellan L, Calvi A, Colledan M, et al. Pretransplant management of basilar artery aneurysm and moyamoya disease in a child with Alagille syndrome. Liver Transpl. 2015;21(9):1227–30. Wiley-Blackwell.

    Article  PubMed  Google Scholar 

  73. Grammatikopoulos T, Sambrotta M, Strautnieks S, Foskett P, Knisely AS, Wagner B, et al. Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis. J Hepatol. 2016;65(6):1179–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Girard M, Bizet AA, Lachaux A, Gonzales E, Filhol E, Collardeau-Frachon S, et al. DCDC2 mutations cause neonatal sclerosing cholangitis. Hum Mutat. 2016;37(10):1025–9. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  75. Verhoeven NM, Huck JHJ, Roos B, Struys EA, Salomons GS, Douwes AC, et al. Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am J Hum Genet. 2001;68(5):1086–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Ng BG, Freeze HH. Perspectives on glycosylation and its congenital disorders. Trends Genet. 2018;34(6):466–76.

    Article  CAS  PubMed  Google Scholar 

  77. Marques-da-Silva D, Reis Ferreira dos V, Monticelli M, Janeiro P, Videira PA, Witters P, et al. Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature. J Inherit Metab Dis. 2017;40(2):195–207. 6th ed. Springer Netherlands.

    Article  CAS  PubMed  Google Scholar 

  78. Jansen JC, Cirak S, van Scherpenzeel M, Timal S, Reunert J, Rust S, et al. CCDC115 deficiency causes a disorder of Golgi homeostasis with abnormal protein glycosylation. Am J Hum Genet. 2016;98(2):310–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Morrow G, Tanguay RM. Biochemical and clinical aspects of hereditary tyrosinemia type 1. Adv Exp Med Biol. 2017;959(11):9–21. 8th ed. Cham: Springer International Publishing.

    Article  CAS  PubMed  Google Scholar 

  80. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis. 2001;21(4):563–71. Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662.

    Article  CAS  PubMed  Google Scholar 

  81. Dimmock D, Kobayashi K, Iijima M, Tabata A, Wong LJ, Saheki T, et al. Citrin deficiency: a novel cause of failure to thrive that responds to a high-protein, low-carbohydrate diet. Pediatrics. 2007;119(3):e773–7.

    Article  PubMed  Google Scholar 

  82. Fiermonte G, Soon D, Chaudhuri A, Paradies E, Lee PJ, Krywawych S, et al. An adult with type 2 citrullinemia presenting in Europe. N Engl J Med. 2008;358(13):1408–9.

    Article  CAS  PubMed  Google Scholar 

  83. Cui H, Li F, Chen D, Wang G, Truong CK, Enns GM, et al. Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders. Genet Med. 2013;15(5):388–94. Springer Nature.

    Article  CAS  PubMed  Google Scholar 

  84. Dames S, Chou L-S, Xiao Y, Wayman T, Stocks J, Singleton M, et al. The development of next-generation sequencing assays for the mitochondrial genome and 108 nuclear genes associated with mitochondrial disorders. J Mol Diagn. 2013;15(4):526–34. Elsevier.

    Article  CAS  PubMed  Google Scholar 

  85. Spinazzola A, Invernizzi F, Carrara F, Lamantea E, Donati A, Dirocco M, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis. 2008;32(2):143–58. Springer Netherlands.

    Article  PubMed  CAS  Google Scholar 

  86. Gotti G, Marseglia A, De Giacomo C, Iascone M, Sonzogni A, D’Antiga L. Neonatal Jaundice with splenomegaly: not a common pick. Fetal Pediatr Pathol. 2016;35(2):108–11.

    Article  PubMed  Google Scholar 

  87. Nicastro E, D’Antiga L. Next generation sequencing in pediatric hepatology and liver transplantation. Liver Transpl. 2018;24(2):282–93. Wiley-Blackwell.

    Article  PubMed  Google Scholar 

  88. Arnell H, Papadogiannakis N, Zemack H, Knisely AS, Nemeth A, Fischler B. Follow-up in children with progressive familial intrahepatic cholestasis after partial external biliary diversion. J Pediatr Gastroenterol Nutr. 2010;51(4):494–9.

    Article  PubMed  Google Scholar 

  89. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5):1645–55. Wiley-Blackwell.

    Article  CAS  PubMed  Google Scholar 

  90. Emerick KM, Elias MS, Melin-Aldana H, Strautnieks S, Thompson RJ, Bull LN, et al. Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion. BMC Gastroenterol. 2008;8:47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Riello L, D’Antiga L, Guido M, Alaggio R, Giordano G, Zancan L. Titration of bile acid supplements in 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr Gastroenterol Nutr. 2010;50(6):655–60.

    Article  CAS  PubMed  Google Scholar 

  92. Miyagawa-Hayashino A, Egawa H, Yorifuji T, Hasegawa M, Haga H, Tsuruyama T, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl. 2009;15(6):610–8. Wiley-Blackwell.

    Article  PubMed  Google Scholar 

  93. Usui M, Isaji S, Das BC, Kobayashi M, Osawa I, Iida T, et al. Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1: a case report. Pediatr Transplant. 2009;13(5):611–4. Wiley/Blackwell (10.1111).

    Article  PubMed  Google Scholar 

  94. Nicastro E, Stéphenne X, Smets F, Fusaro F, de Magnée C, Reding R, et al. Recovery of graft steatosis and protein-losing enteropathy after biliary diversion in a PFIC 1 liver transplanted child. Pediatr Transplant. 2012;16(5):E177–82.

    Article  PubMed  Google Scholar 

  95. Jara P, Hierro L, Martínez-Fernández P, Alvarez-Doforno R, Yánez F, Diaz MC, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med. 2009;361(14):1359–67. Massachusetts Medical Society.

    Article  CAS  PubMed  Google Scholar 

  96. Patel KR, Harpavat S, Finegold M, Eldin K, Hicks J, Firan M, et al. Post-transplant recurrent bile salt export pump disease: a form of antibody-mediated graft dysfunction and utilization of C4d. J Pediatr Gastroenterol Nutr. 2017;65(4):364–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy

    Emanuele Nicastro & Lorenzo D’Antiga

Authors
  1. Emanuele Nicastro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo D’Antiga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuele Nicastro .

Editor information

Editors and Affiliations

  1. Paediatric Hepatology, Gastroenterology and Transplantation, Hospital Papa Giovanni XXIII Bergamo, Bergamo, Italy

    Lorenzo D'Antiga

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nicastro, E., D’Antiga, L. (2019). Genetic Cholestatic Disorders. In: D'Antiga, L. (eds) Pediatric Hepatology and Liver Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-96400-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96400-3_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96399-0

  • Online ISBN: 978-3-319-96400-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation